New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for ...

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Two undergraduate medicine students at University of Galway have led a major study examining how cardioprotective ...

The annual prevalence increased to 0.4% by 2022, with an estimated 854,728 adults without diabetes using GLP-1 RAs. HealthDay News — Among US adults without diabetes, the use of glucagon-like ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the ... and epidemiological data, that GLP-1 receptor stimulation in the brain has neuroprotective ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

As earlier outlined, short-term studies in animals and humans have shown GLP-1 to have some direct vasorelaxation action, cardioprotective effects in models of ischemia-reperfusion injury ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...